Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.
Roger Stupp, MD
Advertisement
Articles by Roger Stupp, MD
Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields.
Advertisement
Latest Updated Articles
Adding TTFields to Chemotherapy to Improves Survival in GlioblastomaPublished: January 18th 2018 | Updated:
Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain CancerPublished: November 19th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
